779 patents
Page 17 of 39
Utility
Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives
22 Feb 22
Brian Stephen Gerstenberger, Andrew Fensome, Dafydd Rhys Owen, Matthew Frank Brown, Matthew Merrill Hayward, Felix Vajdos, Li Huang Xing, Stephen Wayne Wright
Filed: 9 Aug 18
Utility
Tofacitinib oral sustained release dosage forms
22 Feb 22
The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof.
Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
Filed: 13 Mar 20
Utility
Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof
22 Feb 22
The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide.
Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane
Filed: 29 Sep 20
Utility
Combination of a PD-1 Antagonist, an Atr Inhibitor and a Platinating Agent for the Treatment of Cancer
17 Feb 22
The present invention relates to combination therapies useful for the treatment of cancer.
Marat Alimzhanov, Patricia Soulard, Frank Zenke, Heike Dahmen, Astrid Zimmermann, Andreas Schroeder, Keyvan Tadjalli Mehr, Martin Falk
Filed: 26 Sep 19
Utility
Ssi Cells with Predictable and Stable Transgene Expression and Methods of Formation
17 Feb 22
Mammalian cells are described that includes a recombination target site integrated within high integrating locus.
PETER M. O'CALLAGHAN, STEPHEN BEVAN, ROBERT YOUNG, PETER FRASER, LIN ZHANG
Filed: 1 Oct 19
Utility
Bicyclic fused pyridine compounds as inhibitors of TAM kinases
15 Feb 22
Shelley Allen, Mark Laurence Boys, Adam Cook, John Gaudino, Ronald Jay Hinklin, Ellen Laird, Oren T. McNulty, Andrew T. Metcalf, Brad Newhouse, John E. Robinson
Filed: 5 Dec 18
Utility
Substituted Quinoxaline Compounds As Inhibitors of FGFR Tyrosine Kinases
10 Feb 22
James F. Blake, Li REN, David A. MORENO, Shane M. WALLS
Filed: 16 Dec 19
Utility
Recombinant Vaccinia Virus
3 Feb 22
The present disclosure provides human IL-2 variants, recombinant oncolytic viruses comprising the IL-2 variant, compositions comprising the IL-2 variant or recombinant oncolytic virus, and use of the IL-2 variants, recombinant oncolytic virus, or compositions for treating cancer in an individual.
Joseph John Binder, Michael Dale Eisenbraun, Clare Lees, Jeremy Shawn Myers, James Travis Patterson
Filed: 9 Jul 21
Utility
Combinations For Treatment Of NASH/NAFLD And Related Diseases
27 Jan 22
The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
William Paul Esler, Trenton Thomas Ross
Filed: 11 Oct 21
Utility
Crystalline Forms of 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA Maleate
27 Jan 22
This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
Eric Christian Hansen, Christopher Scott Seadeek, Anil Mahadeo Rane
Filed: 6 Oct 21
Utility
Btla Fusion Protein Agonists and Uses Thereof
27 Jan 22
The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response.
Carl F. WARE, John SEDY, Tigran AIVAZIAN, Brian MILLER, Natasha K. CRELLIN
Filed: 1 Mar 21
Utility
Crystalline Forms of 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA Maleate
27 Jan 22
This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
Eric Christian Hansen, Christopher Scott Seadeek
Filed: 6 Oct 21
Utility
Pneumococcal Dosing Regimen
27 Jan 22
Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided.
George Rainer Siber, Peter R. Paradiso, Jill Hackell, Stephen Paul Lockhart, William P. Hausdorff
Filed: 5 Oct 21
Utility
Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
20 Jan 22
The present invention relates to new glycoconjugates comprising Streptococcus pneumoniae capsular saccharide antigens and uses thereof.
Avvari Krishna Prasad, Jianxin Gu, Jin-Hwan Kim, Suddham Singh
Filed: 9 Dec 19
Utility
Therapeutic Antibodies and Their Uses
20 Jan 22
The present invention relates to antibodies that specifically bind to B7-H4 (B7 Homology 4, encoded by gene VTCN1) and bispecific antibodies that specifically bind to both B7-H4 and CD3 (Cluster of Differentiation 3), and polynucleotides, pharmaceutical compositions and methods and uses thereof.
JAMES REASONER APGAR, ANDREA THERESE HOOPER, MALGORZATA AGNIESZKA NOCULA-LUGOWSKA, LEI WU
Filed: 16 Jul 21
Utility
Compounds and Methods for the Treatment of COVID-19
20 Jan 22
Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Martin Youngjin Pettersson, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
Filed: 1 Jul 21
Utility
Cyclin dependent kinase inhibitors
11 Jan 22
Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
Filed: 29 Jul 20
Utility
Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors
11 Jan 22
Hui Li, Seiji Nukui, Stephanie Anne Scales, Min Teng, Chunfeng Yin
Filed: 17 Apr 19
Utility
Immunogenic Compositions and Uses Thereof
6 Jan 22
The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant.
Annaliesa Sybil Anderson, Leena Shriram Bagle, Amardeep Singh Bhupender Bhalla, Miguel Angel Garcia, Lei Hu, Lakshmi Khandke, Avvari Krishna Prasad, Cindy Xudong Yang
Filed: 14 Sep 21
Utility
Compounds and Methods of Use
6 Jan 22
This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity.
Roopa Rai, Sarvajit Chakravarty, Brahmam Pujala, Bharat Uttam Shinde, Anjan Kumar Nayak, Anil Kumar Agarwal, Sreekanth A. Ramachandran, Son Minh Pham
Filed: 22 May 21